JP7395480B2 - フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 - Google Patents

フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 Download PDF

Info

Publication number
JP7395480B2
JP7395480B2 JP2020538987A JP2020538987A JP7395480B2 JP 7395480 B2 JP7395480 B2 JP 7395480B2 JP 2020538987 A JP2020538987 A JP 2020538987A JP 2020538987 A JP2020538987 A JP 2020538987A JP 7395480 B2 JP7395480 B2 JP 7395480B2
Authority
JP
Japan
Prior art keywords
certain embodiments
mixture
compound
acid
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538987A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019139869A5 (https=
JP2021510168A (ja
JP2021510168A5 (https=
Inventor
デウジ ナズニーン
Original Assignee
クラ セラピューティクス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クラ セラピューティクス， エルエルシー filed Critical クラ セラピューティクス， エルエルシー
Publication of JP2021510168A publication Critical patent/JP2021510168A/ja
Publication of JPWO2019139869A5 publication Critical patent/JPWO2019139869A5/ja
Publication of JP2021510168A5 publication Critical patent/JP2021510168A5/ja
Priority to JP2023144990A priority Critical patent/JP2023182589A/ja
Application granted granted Critical
Publication of JP7395480B2 publication Critical patent/JP7395480B2/ja
Priority to JP2025165134A priority patent/JP2026021312A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020538987A 2018-01-10 2019-01-08 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用 Active JP7395480B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023144990A JP2023182589A (ja) 2018-01-10 2023-09-07 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
JP2025165134A JP2026021312A (ja) 2018-01-10 2025-10-01 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615869P 2018-01-10 2018-01-10
US62/615,869 2018-01-10
PCT/US2019/012608 WO2019139869A1 (en) 2018-01-10 2019-01-08 Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023144990A Division JP2023182589A (ja) 2018-01-10 2023-09-07 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用

Publications (4)

Publication Number Publication Date
JP2021510168A JP2021510168A (ja) 2021-04-15
JPWO2019139869A5 JPWO2019139869A5 (https=) 2022-01-18
JP2021510168A5 JP2021510168A5 (https=) 2022-01-18
JP7395480B2 true JP7395480B2 (ja) 2023-12-11

Family

ID=65411932

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020538987A Active JP7395480B2 (ja) 2018-01-10 2019-01-08 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
JP2023144990A Pending JP2023182589A (ja) 2018-01-10 2023-09-07 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
JP2025165134A Pending JP2026021312A (ja) 2018-01-10 2025-10-01 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023144990A Pending JP2023182589A (ja) 2018-01-10 2023-09-07 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
JP2025165134A Pending JP2026021312A (ja) 2018-01-10 2025-10-01 フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用

Country Status (7)

Country Link
US (3) US11701334B2 (https=)
EP (1) EP3737382A1 (https=)
JP (3) JP7395480B2 (https=)
AU (2) AU2019207491A1 (https=)
CA (1) CA3087856A1 (https=)
TW (2) TWI823890B (https=)
WO (1) WO2019139869A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7395480B2 (ja) 2018-01-10 2023-12-11 クラ セラピューティクス， エルエルシー フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
EP3997068A1 (en) * 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
CA3146159A1 (en) * 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508906A (ja) 2002-07-05 2006-03-16 サイクラセル・リミテッド ビスアリールスルホンアミド化合物及び癌の治療におけるその使用
JP2007528387A (ja) 2004-03-10 2007-10-11 ファイザー・プロダクツ・インク 置換されたヘテロアリール−およびフェニルスルファモイル化合物
JP2008509165A (ja) 2004-08-06 2008-03-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ β−セクレターゼ（ＢＡＣＥ）のインヒビターとして有用な２−アミノ−キナゾリン誘導体
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
JP2009520738A (ja) 2005-12-22 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｃｃｒ９活性の阻害剤
JP2010514687A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体
US20100152125A1 (en) 2007-03-20 2010-06-17 Brandeis University Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases
JP2012526128A (ja) 2009-05-06 2012-10-25 プレキシコン インコーポレーテッド スルホンアミドおよびアミノ酸の固体形態
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
WO2016090317A1 (en) 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
WO2016164685A1 (en) 2015-04-10 2016-10-13 Ohio University Compositions and methods for traumatized tissues using zinc chelators
WO2021007474A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2608506A (en) * 1949-08-20 1952-08-26 Sharp & Dohme Inc Arylsulfamyl benzoic acids
US3954994A (en) 1968-10-03 1976-05-04 Pfizer Inc. Intermediates for preparing hipolipemic agents and method of lowering the blood lipid level in mammals with said agents
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
GB9800750D0 (en) 1998-01-14 1998-03-11 Lilly Co Eli Pharmaceutical compound
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
US7279578B2 (en) 2002-10-11 2007-10-09 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
GB0405193D0 (en) 2004-03-08 2004-04-21 Medical Res Council Compounds
JP4464926B2 (ja) 2006-01-25 2010-05-19 ニューロテック ファーマシューティカルズ カンパニー リミテッド 中枢神経系の急性及び慢性的損傷に起因した神経変性を防止するための化合物、組成物及び方法
JP2008308493A (ja) 2007-05-17 2008-12-25 Kissei Pharmaceut Co Ltd 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
ES2761295T3 (es) 2009-03-02 2020-05-19 Stemsynergy Therapeutics Inc Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula
RU2011148937A (ru) 2009-05-01 2013-06-10 Раквалиа Фарма Инк. Производные сульфамоилбензойной кислоты в качестве антагонистов trpm8
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム， エルエルシー． 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
CN104211666B (zh) 2013-05-31 2017-11-14 中国人民解放军军事医学科学院毒物药物研究所 2,3‑环氧丁二酰胺类化合物、其制备方法和用途
US10858316B2 (en) 2015-07-10 2020-12-08 University Of Maryland, Baltimore Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof
WO2017160069A1 (ko) 2016-03-15 2017-09-21 재단법인 의약바이오컨버젼스연구단 신규한 벤젠설폰아미드 유도체 및 이의 용도
CN109081818B (zh) 2017-06-14 2022-04-22 南京华威医药科技集团有限公司 新型吲哚胺2,3-双加氧化酶抑制剂
CN109651208B (zh) 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物，其药物组合物及其用途
JP7395480B2 (ja) * 2018-01-10 2023-12-11 クラ セラピューティクス， エルエルシー フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
CN109293537A (zh) 2018-11-12 2019-02-01 中国药科大学 磺酰胺类化合物及其医药用途
EP3997068A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508906A (ja) 2002-07-05 2006-03-16 サイクラセル・リミテッド ビスアリールスルホンアミド化合物及び癌の治療におけるその使用
JP2007528387A (ja) 2004-03-10 2007-10-11 ファイザー・プロダクツ・インク 置換されたヘテロアリール−およびフェニルスルファモイル化合物
JP2008509165A (ja) 2004-08-06 2008-03-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ β−セクレターゼ（ＢＡＣＥ）のインヒビターとして有用な２−アミノ−キナゾリン誘導体
JP2009520738A (ja) 2005-12-22 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｃｃｒ９活性の阻害剤
JP2010514687A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体
US20100152125A1 (en) 2007-03-20 2010-06-17 Brandeis University Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
JP2012526128A (ja) 2009-05-06 2012-10-25 プレキシコン インコーポレーテッド スルホンアミドおよびアミノ酸の固体形態
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
WO2016090317A1 (en) 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
WO2016164685A1 (en) 2015-04-10 2016-10-13 Ohio University Compositions and methods for traumatized tissues using zinc chelators
WO2021007474A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
日本老年医学会雑誌，2012年，Vol.49, No.4，pp.419-424

Also Published As

Publication number Publication date
US20210052525A1 (en) 2021-02-25
JP2023182589A (ja) 2023-12-26
US11701334B2 (en) 2023-07-18
CA3087856A1 (en) 2019-07-18
TW201929846A (zh) 2019-08-01
JP2021510168A (ja) 2021-04-15
US20240016768A1 (en) 2024-01-18
JP2026021312A (ja) 2026-02-10
EP3737382A1 (en) 2020-11-18
TWI823890B (zh) 2023-12-01
AU2024259810A1 (en) 2024-11-28
WO2019139869A1 (en) 2019-07-18
AU2019207491A1 (en) 2020-07-30
US20250177334A1 (en) 2025-06-05
TW202406538A (zh) 2024-02-16

Similar Documents

Publication Publication Date Title
US20250177334A1 (en) Pharmaceutical Compositions Comprising Phenylsulfonamides, and Their Therapeutic Applications
US20230233562A1 (en) Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
US12220399B2 (en) Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
WO2022242582A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
US20220274922A1 (en) Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
US20220274921A1 (en) Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
US20240226101A1 (en) Pyrimidinylaminobenzenes for lung cancer treatment
US10045972B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US20230165823A1 (en) Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
TWI915305B (zh) 包含二羧酸之醫藥組合物及其治療應用
WO2010112092A1 (en) Compounds for treatment of duchenne musculary dystrophy
CN120641107A (zh) 用于治疗炎症性肠病的含磷化合物
WO2010112091A1 (en) Compounds for treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231129

R150 Certificate of patent or registration of utility model

Ref document number: 7395480

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150